The University of Wollongong (UOW) will establish a world first facility to enable the development of bioinks and customised bioprinting systems for targeted clinical applications. This will be greatly facilitated by the award of a $400,000 grant from MTPConnect – the Medical Technologies and Pharmaceuticals Industry Growth Centre.   Building on the expertise and resources of the ARC Centre of Excellence for Electromaterials Science (ACES) and the Australian National Fabrication Facility (ANFF) Materials Node, both headquartered at UOW, the funding will be used to engage with Small Medium Enterprises (SMEs) to develop projects such as ‘bioinks’ from seaweed (with Venus Shell Systems), customised delivery systems to treat conditions of the eye- the ‘iFixPen’ (with Sydney Eye Bank) and the ‘biopen’ (with SMR automotive and St Vincent’s Hospital Melbourne) for cartilage regeneration.

 

The MTP Bioprint Facility project is being led by ACES and ANFF Materials node Director Professor Gordon Wallace. The aim of the project is to expedite the development of commercial opportunities in 3D bioprinting and identify opportunities with clinical partners, partner SME’s and other industries to enable production of relevant biomaterials, formulations of bioinks and customised bioprinting systems.

Professor Wallace said the project will address the current and future need for delivering 3D printing globally for research, applied science, medical devices and diagnostics and advanced therapeutics.